NEW YORK, Jan. 9 (GenomeWeb News) - AstraZeneca modified its agreement with BTG and DxS over licenses for the Amplification Refractory Mutation System, the companies said today.
Under the improved agreement, BTG and DxS can grant licenses to ARMS and related technologies to other companies.
The original agreement, signed in March 2004, gave BTG and DxS intellectual property rights to commercialize the technology within the diagnostic and research markets.
ARMS is used to detect gene mutations and SNPs.
Details on the agreement were not disclosed.